Analyst Price Targets — OLMA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 11, 2026 11:20 am | — | Goldman Sachs | $20.00 | $11.94 | TheFly | Olema Oncology price target lowered to $20 from $23 at Goldman Sachs |
| May 13, 2026 10:41 am | — | Guggenheim | $35.00 | $13.97 | TheFly | Olema Oncology price target lowered to $35 from $38 at Guggenheim |
| March 9, 2026 3:59 pm | Emily Bodnar | H.C. Wainwright | $38.00 | $16.45 | StreetInsider | Olema Pharmaceuticals (OLMA) PT Lowered to $38 at H.C. Wainwright |
| February 10, 2026 9:11 pm | — | Stifel Nicolaus | $48.00 | $23.37 | TheFly | Olema Oncology initiated with a Buy at Stifel |
| January 7, 2026 10:18 am | — | Piper Sandler | $40.00 | $25.04 | TheFly | Olema Oncology initiated with an Overweight at Piper Sandler |
| January 7, 2026 5:49 am | Michael Yee | UBS | $45.00 | $25.04 | StreetInsider | UBS Starts Olema Pharmaceuticals (OLMA) at Buy |
| December 11, 2025 1:56 pm | — | Oppenheimer | $48.00 | $31.66 | TheFly | Olema Oncology price target raised to $48 from $45 at Oppenheimer |
| December 11, 2025 11:52 am | — | Goldman Sachs | $38.00 | $30.68 | TheFly | Olema Oncology price target raised to $38 from $26 at Goldman Sachs |
| December 11, 2025 11:41 am | Emily Bodnar | H.C. Wainwright | $45.00 | $32.22 | StreetInsider | Olema Pharmaceuticals (OLMA) PT Raised to $45 at H.C. Wainwright |
| December 10, 2025 7:20 pm | Michael Yee | Jefferies | $43.00 | $30.66 | TheFly | Olema Oncology price target raised to $43 from $30 at Jefferies |
Latest News for OLMA
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
Connor Clark and Lunn Investment Management Ltd. bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) during the second quarter, according to its most recent filing with the SEC. The firm bought 66,163 shares of the company's stock, valued at approximately $828,000. Connor Clark and Lunn Investment Management Ltd. owned about 0.08%
Olema Pharmaceuticals Inc. (NASDAQ:OLMA) shares are trading lower on Tuesday as the company completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in the first quarter of 2027.
SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to seven new employees to purchase an aggregate of 254,540 shares of the Company's…
Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OLMA.
U.S. House Trading
No House trades found for OLMA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.